US-based biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics Sirnaomics Ltd. (Stock Code: 2257.HK) announced on Wednesday, that it has partnered with United States-based Gore Range Capital LLC to set up of a joint venture, Sagesse Bio, Inc.

The joint venture is intended to advance Seranomics' novel RNAi therapeutic products into aesthetic medicine.

Sagesse Bio, Inc., a Delaware corporation, combines the strength of Sirnaomics' leadership in RNAi-based technology and product development for focal fat reduction and Gore Range Capital's expertise in skin health industry and financial resources, to accelerate clinical development of the company's innovative products for dealing with a fast-growing aesthetic medicine market. Sagesse Bio intends to advance Sirnaomics lead compound that is IND-enabled and presently in Phase II clinical trials for other indications.

Dr Patrick Lu, Sirnaomics founder, chairman of the board, executive director, president and CEO, said, 'We are thrilled to build this historic partnership: RNAi therapeutic candidate is moving into medical aesthetic product development for body contouring. The joint expertise and resources from both Sirnaomics and Gore Range Capital are setting up a strong foundation for a tremendous growth potential of Sagesse Bio with its accelerated product development speed.'